Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Istanbul Universitesi Rektolugu manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This single action is the only active procedural requirement for the organization at this time.
The prosecution is being conducted by 1 distinct examiner in 1 distinct art unit. With 1 pending office action assigned to 1 examiner, the company's current patenting activities are highly focused. This structure simplifies the management of the portfolio by limiting the number of distinct examiner interactions and technical divisions involved.
HAGHIGHATIAN, MINA is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner is the sole individual responsible for the company's current pending workload. The company's prosecution strategy must address the specific requirements of this examiner within the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.1% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245053 | USE OF ACTIVE SUBSTANCES WITH ANTIVIRAL, ANTI MALARIAL, AND/OR MUCOLYTIC PROPERTIES IN THE TREATMENT OF VIRAL LUNG DISEASES INCLUDING COVID-19 BY SOFT MIST INHALER OR VIBRATION MESH TECHNOLOGY NEBULIZER THROUGH INHALATION ROUTE | HAGHIGHATIAN, MINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245053 | USE OF ACTIVE SUBSTANCES WITH ANTIVIRAL, ANTI MALARIAL, AND/OR MUCOLYTIC PROPERTIES IN THE TREATMENT OF VIRAL LUNG DISEASES INCLUDING COVID-19 BY SOFT MIST INHALER OR VIBRATION MESH TECHNOLOGY NEBULIZER THROUGH INHALATION ROUTE | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18245053 | USE OF ACTIVE SUBSTANCES WITH ANTIVIRAL, ANTI MALARIAL, AND/OR MUCOLYTIC PROPERTIES IN THE TREATMENT OF VIRAL LUNG DISEASES INCLUDING COVID-19 BY SOFT MIST INHALER OR VIBRATION MESH TECHNOLOGY NEBULIZER THROUGH INHALATION ROUTE | HAGHIGHATIAN, MINA | 1616 | §102§103§112 | Final Rejection | — | Pending | Mar 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial